Citations

Showing 10 of 108104 citations.

Advance Care Planning in Cognitively Impaired Older Adults
Thomas, Jane deLima , Sanchez‐Reilly, Sandra, Bernacki, Rachelle , O'Neill, Lynn Bunch, Morrison, Laura , Kapo, Jennifer, Periyakoil, Vyjeyanthi S. , Carey, Elise C.

Mayo Clinic

Journal of the American Geriatrics Society | September 11, 2018 | Volume: 66 | Issue: 8 | Pages: 1469-1474

10.1111/jgs.15471 | PMID 30277566 Get It

Older adults with cognitive impairment face many healthcare challenges, chief among them participating in medical decision‐making about their own health care. Advance care planning (ACP) is the process whereby individuals communicate their wishes for future care with their clinicians and surrogate decision‐makers while they are still able to do so. ACP has been shown to improve important outcomes for individuals with cognitive impairment, but rates of ACP for these individuals are low because of individual‐, clinician‐, and system‐related factors. Addressing ACP early in the illness trajectory can maximize the chances that people can participate meaningfully. This article recommends best practices for approaching ACP for older adults with cognitive impairment. The importance of providing anticipatory guidance and eliciting values to guide future care to create a shared framework between clinicians, individuals, and surrogate decision‐makers is emphasized. It is recommended that ACP be approached as an iterative process to continue to honor and support people's wishes as cognitive impairment progresses and increasingly threatens independence and function. The article describes effective strategies for assessing decision‐making capacity, identifying surrogate decision‐makers, and using structured communication tools for ACP. It also provides guidelines for documentation and billing. Finally, special considerations for individuals with advanced dementia are described, including the use of artificial hydration and nutrition, decisions about site of care, and the role of hospice care.
A Monte‐Carlo‐based and GPU‐accelerated 4D‐dose calculator for a pencil beam scanning proton therapy system
Pepin, M. , Tryggestad, E., Tseung, Hok Seum Wan Chan, Johnson, J. , Herman, Michael , Beltran, Chris , Pepin, Mark D, Tryggestad, Erik, Wan Chan Tseung, Hok Seum, Johnson, Jedediah E, Herman, Michael G., Beltran, Chris J , Pepin, Mark D

Mayo Clinic

Medical Physics | September 11, 2018 | Volume: 45 | Issue: 11 | Pages: 5293-5304

10.1002/mp.13182 | PMID 30203550 Get It

PurposeThe presence of respiratory motion during radiation treatment leads to degradation of the expected dose distribution, both for target coverage and healthy tissue sparing, particularly for techniques like pencil beam scanning proton therapy which have dynamic delivery systems. While tools exist to estimate this degraded four‐dimensional (4D) dose, they typically have one or more deficiencies such as not including the particular effects from a dynamic delivery, using analytical dose calculations, and/or using nonphysical dose‐accumulation methods. This work presents a clinically useful 4D‐dose calculator that addresses each of these shortcomings.MethodsTo quickly compute the 4D dose, the three main tasks of the calculator were run on graphics processing units (GPUs). These tasks were (a) simulating the delivery of the plan using measured delivery parameters to distribute the plan amongst 4DCT phases characterizing the patient breathing, (b) using an in‐house Monte Carlo simulation (MC) dose calculator to determine the dose delivered to each breathing phase, and (c) accumulating the doses from the various breathing phases onto a single phase for evaluation. The accumulation was performed by individually transferring the energy and mass of dose‐grid subvoxels, a technique that models the transfer of dose in a more physically realistic manner. The calculator was run on three test cases, with lung, esophagus, and liver targets, respectively, to assess the various uncertainties in the beam delivery simulation as well as to characterize the dose‐accumulation technique.ResultsFour‐dimensional doses were successfully computed for the three test cases with computation times ranging from 4–6 min on a server with eight NVIDIA Titan X graphics cards; the most time‐consuming component was the MC dose engine. The subvoxel‐based dose‐accumulation technique produced stable 4D‐dose distributions at subvoxel scales of 0.5–1.0 mm without impairing the total computation time. The uncertainties in the beam delivery simulation led to moderate variations of the dose–volume histograms for these cases; the variations were reduced by implementing repainting or phase‐gating motion mitigation techniques in the calculator.ConclusionsA MC‐based and GPU‐accelerated 4D‐dose calculator was developed to estimate the effects of respiratory motion on pencil beam scanning proton therapy treatments. After future validation, the calculator could be used to assess treatment plans and its quick runtime would make it easily usable in a future 4D‐robust optimization system.
Absolute Lymphocyte Count Thresholds: A Simple, Readily Available Tool to Predict the Risk of Cytomegalovirus Infection After Transplantation
Meesing, Atibordee , Razonable, Raymund R.

Mayo Clinic

Open Forum Infectious Diseases | September 11, 2018 | Volume: 5 | Issue: 10 | Pages: No page available

10.1093/ofid/ofy230 | PMID 30302355 Get It

AbstractThis study of 64 solid organ and hematopoietic stem cell transplant recipients found that peripheral blood absolute lymphocyte count of <610 and <830/µL, respectively, correlated with cytomegalovirus infection. In an era when sophisticated measures of CMV-specific T cells are emerging, we emphasize the utility of the inexpensive and readily-available absolute lymphocyte count.
KMT2A (MLL) rearrangements observed in pediatric/young adult T‐lymphoblastic leukemia/lymphoma: A 10‐year review from a single cytogenetic laboratory
Peterson, Jess F. , Pearce, Kathryn E., Williamson, Cynthia M., Demasi, Jonna C. Benevides, Olson, Renee M., Goble, Tony A., Meyer, Reid G., Greipp, Patricia T. , Benevides Demasi, Jonna C, Peterson, Jess F , Greipp, Patricia T , Baughn, Linda B. , Ketterling, Rhett P.

Mayo Clinic

Genes, Chromosomes and Cancer | September 11, 2018 | Volume: 57 | Issue: 11 | Pages: 541-546

10.1002/gcc.22666 | PMID 30203571 Get It

AbstractT‐lymphoblastic leukemia/lymphoma (T‐ALL/LBL) accounts for approximately 15% of pediatric and 25% of adult ALL. While the underlying frequency of KMT2A (MLL) gene rearrangements has been identified in approximately 4‐8% of T‐ALL/LBL cases, a paucity of literature is available to characterize further the KMT2A rearrangements in pediatric/young adult T‐ALL/LBL. A 10‐year retrospective review was performed to identify KMT2A rearrangements in specimens sent for T‐ALL/LBL fluorescence in situ hybridization studies in patients under the age of 30 years. Of 806 T‐ALL/LBL FISH studies performed on unique individuals, 27 (3.3%) harbored KMT2A rearrangements. Nineteen patients were male and eight were female (M:F ratio, 2.4:1) with ages ranging from 1 to 20 years (mean 12, median 12). Of the 27 cases, nine (33%) had KMT2A/MLLT1 fusions, eight (30%) had KMT2A/AFDN fusions, two (7%) had KMT2A/ELL fusions, and one (4%) had a KMT2A/MLLT10 fusion. In addition, five (19%) had KMT2A rearrangements with unidentified gene fusion partners and two (7%) had 3’KMT2A deletions. Our results indicate that MLLT1 and AFDN account for the majority (63%) of KMT2A gene partners in pediatric/young adult T‐ALL/LBL, while no KMT2A/AFF1 or KMT2A/MLLT3 fusions were observed despite their common identification in B‐ALL and acute myeloid leukemia, respectively. In addition to diagnostic and prognostic value, detecting specific KMT2A fusions may also be of clinical importance in the era of targeted therapies.
Characterization and cost–benefit analysis of automated bioreactor‐expanded mesenchymal stem cells for clinical applications
Russell, Athena , Lefavor, Rebecca, Russell, Athena L, Lefavor, Rebecca C, Zubair, Abba C.

Mayo Clinic

Transfusion | September 10, 2018 | Volume: 58 | Issue: 10 | Pages: 2374-2382

10.1111/trf.14805 | PMID 30203447 Get It

BACKGROUND Expanding quantities of mesenchymal stem cells (MSCs) sufficient to treat large numbers of patients in cellular therapy and regenerative medicine clinical trials is an ongoing challenge for cell manufacturing facilities. STUDY DESIGN AND METHODS We evaluated options for scaling up large quantities of bone marrow–derived MSCs (BM‐MSCs) using methods that can be performed in compliance with Good Manufacturing Practices (GMP). We expanded BM‐MSCs from fresh marrow aspirate in αMEM supplemented with 5% human platelet lysate using both an automated cell expansion system (Quantum, Terumo BCT) and a manual flask‐based method using multilayer flasks. We compared MSCs expanded using both methods and assessed their differentiation to adipogenic and osteogenic tissue, capacity to suppress T‐cell proliferation, cytokines, and growth factor secretion profile and cost‐effectiveness of manufacturing enough BM‐MSCs to administer a single dose of 100 × 10 6 cells per subject in a clinical trial of 100 subjects. RESULTS We have established that large quantities of clinical‐grade BM‐MSCs manufactured with an automated hollow‐fiber bioreactor were phenotypically (CD73, CD90, CD105) and functionally (adipogenic and osteogenic differentiation and cytokine and growth factor secretion) similar to manually expanded BM‐MSCs. In addition, MSC manufacturing costs significantly less and required less time and effort when using the Quantum automated cell expansion system over the manual multilayer flasks method. CONCLUSION MSCs manufactured by an automated bioreactor are physically and functionally equivalent to the MSCs manufactured by the manual flask method and have met the standards required for clinical application.
Haploidentical Stem Cell Transplantation: A Gateway to Infrequent Availability of HLA-Matched Related Donors
Iqbal, Shumaila M , Shaikh, Hira , Faizee, Faizan , Merchant, Ambreen A. , Shaheen, Marwan , Hashmi, Shahrukh K. , Aslam, Hafiz Muhammad , Iqbal, Shumaila Muhammad , Hashmi, Shahrukh K , Shaikh, Hira

Mayo Clinic

Case Reports in Medicine | September 10, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-4

10.1155/2018/2573657 | PMID 30275836 Get It

Haploidentical stem cell transplantation provides a plausible alternative for the patients when a fully matched donor is unavailable. Historically, the decision of considering haploidentical transplant has remained elusive; however, with the recent advances, the consideration of haploidentical grafts as a treatment option has become more apparent for both allografting for diseases and engraftment failure. We are reporting here an anecdotal case of a successful haploidentical engraftment in a patient with the prior graft failure of an HLA-matched related donor. Since the patient was severely alloimmunized, desensitization protocol was utilized before the haploidentical transplant, and the patient after 8 months of her second allogeneic transplantation is doing great with successful engraftment, no relapse, and no graft-versus-host disease (GVHD). Numerous reports pertinent to haploidentical graft have shown favorable outcomes in the graft placement, a decline in the rate of GVHD, and an improvement in the morbidity and mortality in affected individuals. Based on the current reports, haploidentical transplantation might be more feasible and has meaningful implications in the situations where matched donors are infrequent.
Primary sclerosing cholangitis in children versus adults: lessons for the clinic
Adike, Abimbola , Carey, Elizabeth J. , Lindor, Keith D.

Mayo Clinic

Expert Review of Gastroenterology & Hepatology | September 10, 2018 | Volume: 12 | Issue: 10 | Pages: 1025-1032

10.1080/17474124.2018.1521719 | PMID 30199272 Get It

Six degrees of separation: A journey through joint and personal connections
Spinner, Robert J.

Mayo Clinic

Clinical Anatomy | September 10, 2018 | Volume: 32 | Issue: 1 | Pages: 81-83

10.1002/ca.23268 | PMID 30198581 Get It